Mevion Medical Systems, a company specializing in accelerating protons to very high energies, has now received FDA clearance for its new MEVION S250i system for intensity modulated proton therapy. The product features the company’s HYPERSCAN pencil beam scanning technology, that involves “energy layer switching” and automated collimation, which produces a narrow beam of protons to attack tumors. The device is already approved for sale in Europe.
Since proton therapy, unlike gamma ray and X-ray based system, can be used to target specific regions of a tumor in 3D, the MEVION S250i is able to volumetrically cover the whole tumor in every axis with high energy protons. Thanks to precise targeting, therapy sessions can be significantly shortened, allowing for greater utilization of the installation.
The company touts the system’s relatively small footprint, quick patient prep, and reduced overall operating costs. The first facility to receive the new MEVION S250i is the MedStar Georgetown University Hospital in Washington, D.C.
Here’s a video presenting the new S250i with HYPERSCAN:
Product page: MEVION S250i™ with HYPERSCAN…
Via: Mevion…